OpGen and Curetis have entered into a definitive agreement to merge, creating a transatlantic leader in molecular diagnostics focusing on infectious diseases and antimicrobial resistance.

Target Information

On September 4, 2019, OpGen, Inc. (Nasdaq: OPGN), a leader in precision medicine through molecular diagnostics and informatics, and Curetis N.V. (Euronext: CURE), known for developing advanced molecular diagnostic solutions, announced a definitive agreement to merge their operations. This strategic acquisition involves OpGen acquiring Curetis GmbH, a fully-owned subsidiary of Curetis which encompasses the entirety of the Curetis Group's business operations. This merger aims to form a transatlantic company based in the U.S. and listed on Nasdaq, focusing on innovative molecular diagnostics and bioinformatics targeting infectious diseases and antimicrobial resistance (AMR).

The merger not only combines the strengths of both companies but also enhances their portfolio by offering a broad range of commercial-stage diagnostics products that have received CE-IVD and FDA clearances. Both companies focus particularly on leveraging their proprietary technologies including next-generation sequencing (NGS) and artificial intelligence (AI) to rapidly address diagnostic challenges in infectious diseases.

Industry Overview

The molecular diagnostics industry is witnessing rapid growth due to increasing demands for more precise and rapid diagnostic tools in healthcare. In the U.S and Europe, industry trends are moving toward personalized medicine and advanced technological solutions. The ris